Roche reports strong sales growth in the first quarter of 2015

RocheThe Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in Pharmaceuticals, and immunodiagnostics products driving growth in Diagnostics.

In Pharmaceuticals, medicines for HER2-positive breast cancer (Herceptin, Perjeta, Kadcyla) saw very strong growth of 23% as the combination of Perjeta and Herceptin in treatment becomes increasingly widespread. Avastin (+6%), which is used to treat seven different cancers, also continued to grow strongly, with increased use in two recently approved indications, ovarian and cervical cancer, as well as breast and lung cancer. MabThera/Rituxan (+5%), used in treatment for blood cancer and rheumatoid arthritis, also made a significant contribution to growth. Actemra/RoActemra (+27%), for rheumatoid arthritis, benefited from increased demand in early stage treatment and in monotherapy, as well as with the new subcutaneous formulation. Xolair (+28%) continued to grow significantly after its approval for an additional indication, chronic hives, in 2014. There was strong uptake of new products, in particular the newly-acquired medicine Esbriet for idiopathic pulmonary fibrosis and Gazyva/Gazyvaro for chronic lymphocytic leukemia. Generic competition impacted two medicines, Xeloda, a chemotherapy drug and Valcyte, an antiviral medicine. Pegasys, a medicine for hepatitis also declined in the quarter, as a result of competition from a newer generation of treatment.

In Diagnostics, sales increased 6% in the first quarter, with Professional Diagnostics (+6%) driving growth from its immunodiagnostics business. Sales were up 10% in Molecular Diagnostics, 14% in Tissue Diagnostics and 1% in Diabetes Care.

The Swiss franc appreciated against a number of currencies, in particular the euro, after the Swiss National Bank lifted its exchange rate peg in January. The impact of the weaker euro was more than offset by the stronger US dollar. The Japanese yen continued to weaken against the Swiss franc, as did a number of Latin American and other European currencies. Overall, exchange rates had a negative impact of 2 percentage points on first quarter sales growth.

Commenting on the Group's results, Roche CEO Severin Schwan said: "We started the year with strong growth and good uptake of new products. In particular, I am pleased to see continued strong demand for Perjeta for breast cancer, as well as Esbriet, which was recently approved in the US for idiopathic pulmonary fibrosis. During the first quarter, the FDA also granted a second Breakthrough Therapy Designation for our cancer immunotherapy medicine anti-PDL1, for a specific type of lung cancer, in addition to bladder cancer. In Diagnostics, we further broadened the menu for the recently launched cobas 6800/8800 instrument platform. Overall, we are on track to reach our full-year targets for 2015."

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...